#USA #New York #Class Action #Regencell #DOJ Inquiry

Recovery Sought for Investors of Regencell Bioscience Holdings

Overview of the Case

In the wake of troubling legal developments, investors in Regencell Bioscience Holdings Limited (NASDAQ: RGC) are being urged to join a class action lawsuit aimed at recovering losses incurred due to alleged market manipulation and a recent Department of Justice (DOJ) subpoena. This case highlights the intricacies of investment risks and the impact of regulatory scrutiny on volatile stock prices.

On June 11, 2026, SueWallSt announced the filing of the class action suit, inviting shareholders who acquired stocks between October 28, 2024, and October 31, 2025, to explore their eligibility for recovery. The information surfaced when Regencell's shares experienced a staggering drop of 18.56%, closing at $13.56 per share on November 3, 2025, following news of the DOJ's investigation.

The Underlying Issues

Regencell Bioscience had previously set a remarkable market cap of about $14 billion despite its operations displaying significant discrepancies with general expectations. Remarkably, the company operated with just twelve employees and reported zero revenue, all while investing approximately $1 million annually in research and development. This unique realm led to speculation and concern regarding the legitimacy of their market valuation.

The Wall Street Journal pointed out that only a small number of companies within the NASDAQ Biotechnology Index had higher valuations. As the lawsuit claims, this inflated value was the consequence of trading practices that appeared detached from the financial fundamentals of the company, suggesting a vulnerability to market manipulation that Regencell executives either neglected or intentionally disregarded.

Stock Price Turbulence

Investment advisors describe a notable fluctuation in Regencell's stock price that has raised eyebrows:

• - Shares traded under $0.30 at the start of the class period.
• - By May 1, 2025, stocks abruptly rose to $2.03 without any news from the company.
• - A peak was reached on June 17, 2025, where shares soared to an astonishing $78.00—a 48,650% surge from the initial pricing during the class period.
• - Following the zenith, shares rapidly crashed, with a significant plunge reported after the DOJ's subpoena was made public.

Throughout this period, Regencell allegedly attributed stock volatility to external factors like short-selling and social media discussions, rather than addressing the underlying issues contributing to the drastic price changes.

The DOJ Subpoena and Risks

The crux of the investigation revealed in the company's October 31, 2025 annual report disclosed that the DOJ had been examining trading activities related to Regencell. The report indicated an awareness that their operations could face increases in liabilities due to potential fines or penalties stemming from the investigation.

Critics argue that Regencell’s previous communications did not sufficiently outline the risks of manipulation or the scrutiny its operations faced from federal authorities, thus misleading investors.

Call to Action for Investors

Investors affected by Regencell's stock declines are encouraged to gather documentation, such as brokerage records that outline the purchase details including dates and quantities. SueWallSt provides free evaluations to assess eligibility for joining the class action suit, emphasizing that prior sales of RGC shares do not disqualify investors from recovering their losses.

“Our objective is to ensure shareholders are informed of their rights and supported in seeking compensation when companies fail to disclose critical information that impacts their investments,” commented Joseph E. Levi, Esq. from SueWallSt.

For those interested in participating, important dates related to the lawsuit should be noted, particularly the deadline on June 23, 2026, for investors aiming for lead plaintiff status.

Conclusion

As this situation unfolds, the Regencell Bioscience class action lawsuit arrives as a critical opportunity for investors to address the financial damage incurred and to hold accountable those who may have contributed to the misleading of shareholders. Expect greater developments in the coming months as the legal proceedings progress. For more detailed guidance regarding eligibility and processes, contact SueWallSt today.